Evidence map›Paper›PMID 27878205›Full record

ArticleApplied clinical informatics2016

Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing.

Brittany L Melton, Alan J Zillich, Jason Saleem, Alissa L Russ, James E Tisdale, Brian R Overholser

Abstract readEvaluation Study
In one paragraph

Article in Applied clinical informatics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Clinical Decision Support Intervention for Rib Fracture Treatment.Journal of the American College of Surgeons · 2020
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Integrating pharmacogenetic testing into primary care.Expert review of precision medicine and drug development · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Brittany L Melton
Alan J Zillich
Jason Saleem
Alissa L Russ
James E Tisdale
Brian R OverholserBrian R. Overholser, PharmD, FCCP, Associate Professor, Purdue University College of Pharmacy, Research Institute 2: Room 402, 950 W. Walnut St., Indianapolis, IN 46202, Office (317) 278-4001, Fax: (317) 880-0568, Email: boverhol@purdue.edu.

Funding

Probing the Atrial Arrhythmogenic Substrate with Sustained Adrenergic StimulationK08HL095655 · NHLBI · PURDUE UNIVERSITY · PI OVERHOLSER, BRIAN R · 2010 to 2014
$691k
NHLBI NIH HHS K08 HL095655
6 · The paper itself

Abstract

objectivePharmacogenomic-guided dosing has the potential to improve patient outcomes but its implementation has been met with clinical challenges. Our objective was to develop and evaluate a clinical decision support system (CDSS) for pharmacogenomic-guided warfarin dosing designed for physicians and pharmacists.

methodsTwelve physicians and pharmacists completed 6 prescribing tasks using simulated patient scenarios in two iterations (development and validation phases) of a newly developed pharmacogenomic-driven CDSS prototype. For each scenario, usability was measured via efficiency, recorded as time to task completion, and participants' perceived satisfaction which were compared using Kruskal-Wallis and Mann Whitney U tests, respectively. Debrief interviews were conducted and qualitatively analyzed. Usability findings from the first (i.e. development) iteration were incorporated into the CDSS design for the second (i.e. validation) iteration.

resultsDuring the CDSS validation iteration, participants took more time to complete tasks with a median (IQR) of 183 (124-247) seconds versus 101 (73.5-197) seconds in the development iteration (p=0.01). This increase in time on task was due to the increase in time spent in the CDSS corresponding to several design changes. Efficiency differences that were observed between pharmacists and physicians in the development iteration were eliminated in the validation iteration. The increased use of the CDSS corresponded to a greater acceptance of CDSS recommended doses in the validation iteration (4% in the first iteration vs. 37.5% in the second iteration, p<0.001). Overall satisfaction did not change statistically between the iterations but the qualitative analysis revealed greater trust in the second prototype.

conclusionsA pharmacogenomic-guided CDSS has been developed using warfarin as the test drug. The final CDSS prototype was trusted by prescribers and significantly increased the time using the tool and acceptance of the recommended doses. This study is an important step toward incorporating pharmacogenomics into CDSS design for clinical testing.

Indexed as

Decision Support Systems, ClinicalDrug Dosage CalculationsPharmacogeneticsDrug PrescriptionsFemaleHumansMaleWarfarinWarfarinClinical decision support systemscomputer-assisted drug therapyCPOEpharmacogeneticswarfarin

Identifiers

PMID27878205
PMCPMC5228145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.